SEELOS THERAPEUTICS INC - SEEL STOCK NEWS

Seelos Therapeutics (Nasdaq: SEEL) announced a registered direct offering of 8,865,000 shares of common stock at $0.79 per share, aiming for gross proceeds of approximately $7 million. Additionally, in a concurrent private placement, investors will receive warrants to purchase up to 6,648,750 shares at an exercise price of $0.84. The offerings are expected to close around September 9, 2020. Proceeds will be used for general corporate purposes and to advance Seelos' product candidates development.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the Cantor Virtual Global Healthcare Conference from September 15-17, 2020. Raj Mehra, Ph.D., Chairman and CEO, will host individual meetings via conference calls. The company focuses on developing therapies for central nervous system disorders and rare diseases, with a portfolio addressing conditions like Major Depressive Disorder, PTSD, and ALS. For more details on the conference, visit Cantor Healthcare Conference.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) has received Orphan Drug Designation from the European Medicines Agency for its treatment SLS-005 in mucopolysaccharidosis type III (Sanfilippo syndrome). This designation complements prior ODD approvals in the US and Europe for other diseases, including Spinocerebellar Ataxia Type 3 and Oculopharyngeal Muscular Dystrophy. SLS-005 has also been granted Fast Track designation for OPMD, indicating expedited development and review.

Seelos Therapeutics (Nasdaq: SEEL) announced that it has received FDA approval to start a Phase IIb/III trial for SLS-005 (trehalose) aimed at treating Amyotrophic Lateral Sclerosis (ALS). This pivotal study will enroll 160 patients, evaluating the drug's efficacy in preserving motor function and prolonging survival, focusing on several key endpoints over 24 weeks. The company emphasizes trehalose's potential in altering ALS progression, highlighting prior promising preclinical results.

Seelos Therapeutics (Nasdaq: SEEL) announced on July 15, 2020, the grant of a stock option for 50,000 shares at an exercise price of $1.01 to a new employee, in accordance with Nasdaq Listing Rule 5635(c)(4). The option is non-qualified, with vesting occurring over four years, contingent on the employee's continuous employment. This move aims to incentivize talent acquisition as the company develops therapies for central nervous system disorders and rare diseases, including conditions like Major Depressive Disorder and Parkinson's Disease.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the grant of a stock option to purchase 20,000 shares to a new employee under the 2019 Inducement Plan. The exercise price is set at $1.06, based on the closing price on July 1, 2020. The options vest over four years, with 1/4th vesting after one year and the remainder monthly thereafter, contingent on continuous employment. This action is in compliance with Nasdaq Listing Rule 5635(c)(4). Seelos focuses on developing therapies for central nervous system disorders and rare diseases.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) has initiated a preclinical study of SLS-007 targeting Parkinson's disease (PD) using an AAV vector to focus on the non-amyloid component core of alpha synuclein. The study aims to evaluate the protective effects of two peptides, S62 and S71, on dopaminergic function in a rodent model of PD. Top-line data is expected by late 2020/early 2021. The peptides aim to halt α-synuclein aggregation, which is linked to Lewy Bodies, a hallmark of PD.

Seelos Therapeutics announced final safety data from its Phase I study of SLS-002 (intranasal racemic ketamine) for treating Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD). All doses were safe, with no serious adverse events or new safety signals reported. The treatment is set to enter a Proof of Concept study in Fall 2020, involving 16 initial patients followed by 120 in a double-blind study. The FDA has supported the study design, and Seelos aims to explore SLS-002's potential in broader indications.

Seelos Therapeutics (SEEL) has announced a key opinion leader (KOL) call on June 23, 2020, at 1:00 p.m. ET to discuss data from its Phase I study of SLS-002, a treatment aimed at Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD). Dr. Michael E. Thase will lead the discussion, providing insights on mood disorders and answering questions. CEO Raj Mehra will also address the Phase I data and the next trial design. This call signifies Seelos' ongoing commitment to addressing central nervous system disorders.